Eli Lilly and Company, a pharmaceutical company based in Indianapolis, Indiana, revealed it has teamed up with Amazon Pharmacy to help deliver its Zepbound weight loss drug and other medicines straight to customers' homes.
It struck a partnership deal with the online pharmacy subsidiary of Amazon Inc. just four months after obtaining the required regulatory approval to sell its diabetes treatment under a different name and category: weight loss.
Lilly's Weight Loss Treatment
According to CBS News, Eli Lilly's Tirzepatide drug, currently sold as a Mounjaro brand for diabetes, is now on the market under the new name Zepbound. It is also advertised as a weight-loss medication administered using an injection pen.
The company reportedly started selling Zepbound earlier this year. The drugs are directly sold to patients. Patients consult with doctors and obtain prescriptions from digital pharmacies, and the drugs are delivered to them.
Amazon Pharmacy Added as Home Delivery Option
Its partnership with Amazon's pharmacy unit allows patients and customers to obtain their medications quickly. In addition to Amazon Pharmacy, Eli Lilly delivers drugs to its customers via Truepill.
"Lilly has selected Amazon Pharmacy as a dispensing pharmacy option, allowing patients to receive fast, free delivery of medications and 24/7 access to clinical pharmacists," Dr. Vin Gupta, Amazon Pharmacy's chief medical officer, said in a press release. "To help patients being treated for diabetes, obesity, and migraine, Amazon Pharmacy is now offering home delivery of select medications through LillyDirect."
Dr. Gupta added, "Lilly has selected Amazon Pharmacy to serve as a third-party dispensing provider for LillyDirect Pharmacy Solutions, delivering prescribed Lilly medications directly to a patient's home."
Photo by: James Yarema/Unsplash


Scandinavian Tobacco Group Sells BREAK and Moro Brands to Japan Tobacco for €176 Million
ASML Trillion-Dollar Valuation: Can Europe’s AI Chip Giant Reach the Historic Milestone?
Macquarie Names Greg Ward as CEO, Signaling Stability and Strategic Continuity
Chalco Shares Jump as Chinalco Plans Up to $300 Million Stake Increase
OpenAI Australia Data Center Switches Cooling Strategy After Recycled Water Plan Fails
Domino’s Weighs Appeal After Australian Court Rules Workers Were Misled on Pay
Ryanair Warns Summer Airfares May Stay Lower as Quarterly Profit Misses Estimates
IBM Q2 Earnings Miss Estimates as Software Growth Offsets Infrastructure Weakness
Intel, AMD Seek Long-Term China Server CPU Deals as AI Demand Drives Supply Crunch
Samsung Cuts U.S. Consumer Electronics Jobs as Headquarters Moves to Texas
SpaceX Q2 Earnings on Aug. 4 Set Stage for Historic Insider Share Unlock
Super Micro Computer Stock Jumps 20% After Record AI Orders and Margin Surge
Rubio Rejects AI ‘Kill Switch’ Claims as U.S. Defends American Technology Abroad
Belimo H1 Sales Surge as AI Data Center Cooling Drives More Than Half of Growth
Judge Approves Anthropic’s $1.5 Billion AI Copyright Settlement With Authors
Cathay Pacific Sees H1 Profit Surge on Strong Travel Demand
GM Q2 Earnings Beat Estimates as General Motors Raises 2026 Profit Outlook 



